2020.07.28 I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer
2020.06.12 I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II
2020.05.28 I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome
2020.05.21 I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
2020.05.13 First Patient Dosed with I-Mab’s CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
2020.05.04 Genetic Engineering & Biotechnology News (GEN), May 4, 2020: Returning to Work: Biotech Companies in China Rev up to Supply Critical Products Amid COVID-19 Pandemic